2022 Fiscal Year Final Research Report
Development of metastatic bladder cancer treatment using BCG cell wall lipid liposomes in combination with anti-PD-1 antibodies.
Project/Area Number |
20K18089
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 56030:Urology-related
|
Research Institution | University of Tsukuba |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | BCG / ミコール酸 / TDM / 膀胱癌 |
Outline of Final Research Achievements |
Intravesical BCG therapy is the standard therapy to prevent therecurrence and progression of non-muscle invasive bladder cancer.Although it is a highly effective treatment that significantly reduces recurrence rates, it requires the administration of live bacteria, which can lead to serious infections.Therefore, we are eager to develop a non-infectious, non-viable formulation.We focused on trehalose-6 6'-dimycolate (TDM), a wall component specific to acid-fast bacilli including BCG, which has strong immune activity, and we formulated it into hydrophilic liposomes.We found that intraperitoneal administration of TDM-liposome significantly suppressed intravesical carcinogenesis in abladder carcinogenesis model mice.
|
Free Research Field |
膀胱癌
|
Academic Significance and Societal Importance of the Research Achievements |
我々が今回開発したTDMリポソーム製剤はマウスモデルでの膀胱内発癌予防効果を認めたことで、BCGの代替となりつつも感染性のない全く新しい治療法の開発につながる可能性が示唆された。またこのTDMリポソーム製剤は腹腔内投与により発癌予防効果を来したことから、投与方法が膀胱内注入に限られたBCGと異なり、転移性癌や膀胱癌以外の癌腫など、多様な疾患を対象とした抗腫瘍薬の開発につながる可能性があると考えている。
|